26.74 USD
▲+0.47+1.79%
盘后 26.99 +0.93%
2026-09-04
市值
$1.72B
市盈率
—
EPS
-2.63
股息率
—
52 周区间
24.31 – 32.00
成交量
272.08K
Beta
—
目标价
44.33
52W 低 24.3152W 高 32.00
价格走势
公司简介
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.